SecBot SecBot
PRESS-RELEASE ·Filed Aug 10, 2026

AXSM

Axsome Therapeutics, Inc.
MIXED
Impact 6/10
Horizonweeks Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

Revenue growth (46% YoY) and strong early Alzheimer's agitation uptake are tempered by a significant EPS miss and surging SG&A costs. Monitor Q3 2026 for continued AUVELITY Alzheimer's script trajectory and any margin improvement as launch costs stabilize. The AXS-12 PDUFA (May 2027) and solriamfetol BED data (Q4 2026) are key pipeline catalysts.

DirectionMixed
Confidencehigh
Horizonweeks

Drugs in focus

AXSM drug pipeline →

AXS-12

● Neutral Named in this press release
Impact
Phase
Filed/PDUFA (NDA accepted; Phase 3 completed)
Time to market
NDA is already under FDA review; a decision is due by May 1, 2027, with commercial launch in 2027 if approved — roughly 9 months to the binary.
Next catalyst
PDUFA date · May 1, 2027 165d

What to watchWatch for FDA communications ahead of the May 1, 2027 PDUFA, e.g., any newly scheduled advisory committee, labeling discussions, or a potential priority-review/timing change, and treat AXS-12 approval as incremental upside on top of the AUVELITY (incl. Alzheimer's agitation) and SUNOSI commercial story rather than the stock's primary thesis. Near-term share moves are more likely tied to quarterly product sales and the Alzheimer's agitation launch than to AXS-12, since its binary is ~9 months out.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$220.89
T+0 close · Aug 10, 2026 · via day close
Latest settled
−36.80%
T+60 · $139.61
Vs SPY
−34.38%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 10 $220.89entry
  2. T+1 · 3mo ago −2.32%α −2.00% · $215.77
  3. T+5 · 3mo ago −2.09%α −2.04% · $216.27
  4. T+20 · 2mo ago −5.92%α −5.00% · $207.82
  5. T+60 · 14d ago −36.80%α −34.38% · $139.61
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Axsome reported Q2 2026 net product revenue of $218.4M (+46% YoY), beating the $221.8M consensus, but GAAP EPS of -$1.26 missed the -$0.84 consensus by 49.1%. AUVELITY Alzheimer's agitation launch data showed strong early uptake (126% NBRx increase in 65+ patients), and SG&A surged 60% to $208.1M to support the expanded sales force. The net loss widened to $51.3M (-$0.99 GAAP EPS), with no change to full-year guidance but cash runway sufficient into cash-flow positivity.

Key Financial Metrics

EPS
−$1.26
est −$0.84 · -49.1%
Revenue
$218.4M
est $221.8M · -1.5% · +46.0% YoY
Rating
miss

Key Facts

  • Q2 2026 total net product revenue $218.4M (+46% YoY) vs consensus $221.8M (+1.5% beat)
  • GAAP EPS -$1.26 vs consensus -$0.84 (-49.1% miss); GAAP diluted EPS -$0.99 from net loss $51.3M
  • AUVELITY net sales $180.3M (+51% YoY); SUNOSI $35.8M (+20%); SYMBRAVO $2.3M (+461%)
  • SG&A expense $208.1M (+60% YoY) driven by Alzheimer's agitation launch and sales force expansion
  • Net loss $51.3M vs $48.0M in Q2 2025; includes $27.1M in stock-based compensation
  • Cash $319.9M at June 30, 2026 vs $322.9M at Dec 31, 2025; cash runway into cash-flow positivity
  • AUVELITY Alzheimer's agitation launch: NBRx in 65+ patients up 126% in first eight weeks
  • AXS-12 NDA accepted with PDUFA May 1, 2027
  • Phase 3 ENGAGE trial of solriamfetol in BED topline expected Q4 2026
  • Total prescriptions: AUVELITY ~266,000 (+34% YoY); SUNOSI ~61,000 (+14% YoY); SYMBRAVO ~23,500 (+30% QoQ)

Financial Impact

Revenue beat of $218.4M vs $221.8M consensus (+1.5%); EPS miss of -$1.26 vs -$0.84 (-49.1%); net loss widened $51.3M from $48.0M

revenueepsnetLosssgaExpensescashPosition

Risk Factors

  • EPS miss of 49% signals higher-than-expected operating leverage; sustained SG&A growth could pressure margins
  • No formal guidance change; cash runway claims depend on revenue growth trajectory maintaining 46% YoY pace
  • Alzheimer's launch early data (126% NBRx increase) is early and subject to reversion
  • Dilution from stock-based compensation ($27.1M in Q2) and potential future equity needs for pipeline

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (28 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3341699

Track record

26 reports on AXSM

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +14.74% at T+60 after the Apr 30, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 2, 202614d ago 8-K Bullish 6/10 No price data
  2. Nov 2, 202614d ago Press Release Bullish 6/10 Entry $136.01 to $133.96 Now $137.01 +0.74% ▼ −1.51% −1.59% vs SPY
  3. Oct 20, 202627d ago Institutional Cluster Bearish 4/10 Entry $156.31 to $142.20 Now $137.01 +12.35% ▲ +9.03% +8.58% vs SPY
  4. Aug 11, 202613w ago Institutional Cluster Mixed 5/10 Entry $214.66 to $218.20 Now $137.01 −36.17% ▲ +1.65% +2.09% vs SPY
  5. Aug 10, 202614w ago 8-K Neutral 6/10 No price data
  6. Aug 10, 202614w ago Press Release Mixed 6/10 Viewing Entry $220.89 to $216.27 Now $137.01 −37.97% ▼ −2.09% −2.04% vs SPY
  7. Jul 15, 202617w ago Press Release Bullish 6/10 Entry $237.53 to $239.62 Now $137.01 −42.32% ▲ +0.88% +1.86% vs SPY
  8. Jul 9, 202618w ago Court Ruling Bullish 5/10 Entry $248.95 to $237.04 Now $137.01 −44.96% ▼ −4.78% −4.65% vs SPY
  9. Jul 7, 202618w ago Press Release Neutral 4/10 Entry $249.76 to $235.26 Now $137.01 −45.14% ▼ −5.81% −6.36% vs SPY
  10. Jul 1, 202619w ago 144 Neutral 4/10 Entry $244.31 to $248.95 Now $137.01 −43.92% ▲ +1.90% +0.97% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 8h 44m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026